OCUL
Ocular TherapeutixCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
OCUL vs peer average
71/100
OCUL vs. peer average (C vs. D)
Grade spread
B 1 · C 1 · D 2 · F 6
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
FDMT is the first available peer comparator.
Retinal-disease development peer with a wet-AMD program. Its September 28 announcement concerned Phase 3 enrollment in diabetic macular edema, not a new wet-AMD efficacy readout; it is a less direct explanation for OCUL's selloff than Kodiak's DAYBREAK data. [4DMT filing](https://ir.4dmoleculartherapeutics.com/node/11046/html)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
OCUL
Ocular Therapeutix
FDMT
4D Molecular Therapeutics
Grade
C
F
Momentum
5
49
Value
41
41
Sentiment
81
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs FDMT
OCUL / FDMT
Grade Position
Above peers
OCUL vs. peer average (C vs. D)
71/100
Momentum
5
FDMTValue
41
OCULSentiment
81
OCULRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs OCUL
FDMT is the first peer returned for this comparison set.